Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/10/2018 |
| Start Date: | November 5, 2003 |
| End Date: | March 14, 2007 |
A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed Prior Chemotherapy
The purpose of this study is to determine if erlotinib will improve disease at doses that
produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
Only patients with 0 to 1 performance status on the ECOG scale are eligible.
Inclusion Criteria:
- Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or
cytological).
- Received prior chemotherapy treatment for advanced, metastatic non-small cell lung
cancer.
- Measurable disease per RECIST criteria.
- Adequate bone marrow, hepatic and renal function.
Exclusion Criteria:
- Breast cancer or skin cancer at any time in the past or any other cancer in the past 5
years.
- Brain metastases that are unstable, require steroids, are life-threatening or required
radiation in the last 28 days.
- Known hypersensitivity to minocycline.
- History of serious cardiac disease that is not controlled.
- Serious eye conditions.
- Prior treatment with inhibitors of EGFR of any kind.
We found this trial at
1
site
7979 Wurzbach Road
San Antonio, Texas 78229
San Antonio, Texas 78229
Click here to add this to my saved trials
